CN103251669A - Anti-hepatic fibrosis drug composite - Google Patents
Anti-hepatic fibrosis drug composite Download PDFInfo
- Publication number
- CN103251669A CN103251669A CN2013101943817A CN201310194381A CN103251669A CN 103251669 A CN103251669 A CN 103251669A CN 2013101943817 A CN2013101943817 A CN 2013101943817A CN 201310194381 A CN201310194381 A CN 201310194381A CN 103251669 A CN103251669 A CN 103251669A
- Authority
- CN
- China
- Prior art keywords
- hepatic fibrosis
- treatment
- liver
- blood
- hepatic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to an anti-hepatic fibrosis drug composite. The anti-hepatic fibrosis drug composite is characterized by comprising the following crude drugs in parts by weight: 5-15 parts of artemisia anomala, 10-20 parts of geranium wilfordii, 1-5 parts of leeches and 1-5 parts of Zhechong. The anti-hepatic fibrosis drug composite disclosed by the invention can be used for preparing the artemisia anomala, the geranium wilfordii, the leeches and the zhechong into a compound according to a traditional Chinese medicine theory, achieves the purpose of anti-hepatic fibrosis through the synergistic action of the drugs on the aspects of anti-inflammation, anti-necrosis, hepatic cells protection, and the like and has the advantages of low price and easiness for popularization.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition of anti-hepatic fibrosis, be specifically related to a kind of Chinese medicine compound of eutherapeutic anti-hepatic fibrosis.
Background technology
Hepatic fibrosis refers to by connective tissue paraplasm in the liver due to the various virulence factors, causes the pathological process that the diffusivity extracellular matrix excessively precipitates in the liver.It is not an independently disease, and many chronic hepatic diseases all can cause hepatic fibrosis.China is the popular district occurred frequently of viral hepatitis, viral hepatitis be the commonly encountered diseases that causes hepatic fibrosis and liver cirrhosis because of, chronic hepatitis patient reaches tens million of, wherein has an appointment again 1/10 ~ 1/3 can develop into liver cirrhosis.Hepatic fibrosis is the pathologic basis that the various causes of disease cause liver cirrhosis.In recent years, along with the developing rapidly and using of Medical Molecular Biology, the understanding of hepatic fibrosis is deepened continuously, for treatment provides many possible approach.Think that at present hepatic fibrosis is reversible, by the fibrosis treatment degree of hepatic fibrosis is obviously alleviated.And most treatments still are in the experimentation stage at present.The formation of hepatic fibrosis and development are extremely complicated processes; multiple treatment use in conjunction is extremely important in the treatment of hepatic fibrosis, mainly comprises etiological treatment, hepatocyte protection and regenerative therapy, the immunization therapy of hepatic fibrosis, the activation suppression therapy of hepatic stellate cell, the methods such as adjustment for the treatment of of extracellular matrix.Chinese medicine is demonstrating than remarkable advantages aspect the intervention hepatic fibrosis.The method for the treatment of by Chinese herbs hepatic fibrosis has single medicinal material treatment and compound of Chinese medicine.Single medicinal material has Radix Salviae Miltiorrhizae, the Radix Astragali, Radix Et Rhizoma Rhei, Cordyceps, Rhizoma Curcumae etc.The more Chinese medicine compound of research has compound recipe 861 mixture, stilbene art granule, supporting vital QI and dispersing blood stasis 319 sides, the red diisopropylamine dichloroacetate of the Chinese, Herba Sidae Rhombifoliae soup, biejiajian pills etc. at present.Chinese medicine compound has pharmacology's advantage of multicomponent, too many levels, multi-level, many target spots, and its treatment hepatic fibrosis curative effect is more remarkable.
Summary of the invention
The invention provides a kind of pharmaceutical composition of anti-hepatic fibrosis, by the pharmacological action approach of multicomponent, too many levels, multi-level, many target spots, reach the purpose of anti-hepatic fibrosis.
For achieving the above object, the technical solution used in the present invention is: a kind of pharmaceutical composition of anti-hepatic fibrosis, formed by the crude drug of following parts by weight:
Herba Artemisiae Anomalae 5-15 part;
Herba Erodii 10-20 part;
Hirudo 1-5 part;
Female ground beetle 1-5 part.
Related content in the technique scheme is explained as follows:
In the such scheme, in the described pharmaceutical composition each crude drug preferably amount ranges be:
Herba Artemisiae Anomalae 7-13 part;
Herba Erodii 12-18 part;
Hirudo 2-5 part;
Female ground beetle 2-5 part.
Therapeutic mechanism of the present invention is: hepatic fibrosis belongs to the category of traditional Chinese medical science liver blood stasis of blood resistance, and it is long that this type of disease mostly is the course of disease, and touching difficulty heals, prolonged illness consumption impairment of QI blood, and the internal injury Liver and kidney, deficiency-heat is gradually given birth to, and then healthy energy is difficult multiple, and its pathogenesis mostly is qi depression to blood stasis.Pharmaceutical composition of the present invention is from Fibrotic main pathomechanism incision, select for use Herba Artemisiae Anomalae, Herba Erodii, Hirudo, female ground beetle four flavor activating blood and removing stasis drugs to constitute, wherein Herba Erodii He female ground beetle have dredge through, invigorate blood circulation, the effect of blood stasis dispelling, Herba Artemisiae Anomalae and Hirudo can strengthen the effect of promoting blood circulation to remove obstruction in the collateral, improve the hepatic tissue microcirculation, that is to say that Herba Artemisiae Anomalae, Herba Erodii, Hirudo, female ground beetle four flavor activating blood and removing stasis drug synergism can strengthen the curative effect of anti-hepatic fibrosis.Confirm that after deliberation it can make patients with liver fibrosis Serum hyaluronic acid (HA), layer mucoprotein (LN), (IV-C) content significantly descends type, and curative effect is better.According to theory of Chinese medical science, Herba Artemisiae Anomalae, Herba Erodii, Hirudo, female ground beetle are made compound recipe, by the aspect synergism such as antiinflammatory, necrosis and protection hepatocyte of medicine; the hypertrophy that suppresses fat-storing cell; reduce the synthetic of collagen, promote the liver reparation, reach the purpose of anti-hepatic fibrosis.
The pharmacology of each Chinese medicine ingredients and the property of medicine are as follows in the pharmaceutical composition of the present invention:
Herba Artemisiae Anomalae: hardship.Temperature, GUIXIN, liver, spleen channel.The effect removing blood stasis stimulates the menstrual flow, dispersing cold for relieving pain, promoting digestion and removing stagnation." book on Chinese herbal medicine converges " record " Herba Artemisiae Anomalae, start with few the moon, meridian of Foot-TAI YIN.Stimulate the menstrual flow and help the side of removing blood stasis, the agent of the strongly fragrant auxilliary hot perfume that looses.Press the celestial agent of Herba Artemisiae Anomalae removing blood stasis also, its property is apt to away, specially goes into blood system, the bitter in the mouth GUIXIN, and warm property is suitable with the spleen again, so two go into.Lid heart master blood, spleen is wrapped up in blood, so specially treat blood disorder also." can be used for Zhi Liao lumps in the chest and abdomen, jaundice due to damp-heat, edema abdominal distention.Herba Artemisiae Anomalae has the acceleration blood circulation, removes smooth muscle spasm, promotes hemagglutinative function; Decocting liquid can increase Cavia porcellus and irritate the arteries and veins flow, and the anoxia in mice model is had tangible oxygen lack resistant function.
Herba Erodii: hot, bitter, flat.Return the liver,kidney,spleen warp.Cure mainly wind-damp dispelling, the meridian dredging, antidiarrheal profit.Be used for rheumatic arthralgia, numbness contracture, muscles and bones is ached, dysentery.Herba Erodii have dredge through, invigorate blood circulation, the effect of heat clearing away, detoxifcation, dampness removing, damp and hot, the stasis of blood that occurs for chronic hepatitis patient stagnate pent up, qi and blood disorder, therapeutical effect is preferably arranged.
Hirudo: salty, bitter, flat.Slightly poisonous.Return Liver Channel.Removing blood stasis stimulates the menstrual flow, Zhu Yu Xiao Disorder.The Shennong's Herbal record: " main by stagnant blood, blood stasis, the moon closes removing blood stasis, loss of fecundity, dredging water passages." chemical constituent: mainly contain protein.Contain hirudin in the saliva, also contain heparin, antithrombotic element and H-subst.Blood coagulation resisting function: the platelet aggregation that adenosine diphosphate (ADP) (ADP) is induced all has significant inhibitory effect, and can reduce whole blood contrast viscosity and plasma viscosity, shortens erythrocyte electrophoretic time; Hirudo extract, hirudin have the obvious suppression effect to platelet aggregation, suppress the rat thrombus in vivo and form, and disseminated inravascular coagulation is had good therapeutical effect.Hirudin has preventive effect to the thrombosis that bacterial endotoxin causes, and can reduce mortality rate; Improve microcirculation; Hirudo has obvious reduction effect to cholesterol and the triglyceride of experimental hyperlipidemia.Hirudin has inhibitory action to tumor cell, and liver cancer growth is had certain inhibitory action.Because Hirudo has high anticoagulation, thereby be conducive to anticarcinogen and immunologically competent cell and immerse cancerous tissue and kill and wound cancerous cell.
Female ground beetle: female ground beetle then is strong activating blood and removing stasis drug, can play and improve liver microcirculation, improves liver blood and oxygen supply.Modern medicine study thinks that syndrome of blood stasis is present in the whole pathological process of chronic hepatopathy, in close relations with hepatic fibrosis.
The invention has the beneficial effects as follows: prescription of the present invention has good effect of anti hepatic fibrosis, by the pharmacological action approach of multicomponent, too many levels, multi-level, many target spots, reaches the purpose of anti-hepatic fibrosis, the advantage that have at a low price, is easy to promote.
The specific embodiment
Be further described below in conjunction with the present invention of embodiment:
Embodiment one: a kind of pharmaceutical composition of anti-hepatic fibrosis
The pharmaceutical composition prescription is made up of the following raw materials in weight medicine:
Herba Artemisiae Anomalae 10g;
Herba Erodii 15g;
Hirudo 3g;
Female ground beetle 3g.
Embodiment two: a kind of pharmaceutical composition of anti-hepatic fibrosis
The pharmaceutical composition prescription is made up of the following raw materials in weight medicine:
Herba Artemisiae Anomalae 10g;
Herba Erodii 20g;
Hirudo 2g;
Female ground beetle 2g.
Embodiment three: a kind of pharmaceutical composition of anti-hepatic fibrosis
The pharmaceutical composition prescription is made up of the following raw materials in weight medicine:
Herba Artemisiae Anomalae 15g;
Herba Erodii 20g;
Hirudo 5g;
Female ground beetle 5g.
Embodiment four: a kind of pharmaceutical composition of anti-hepatic fibrosis
The pharmaceutical composition prescription is made up of the following raw materials in weight medicine:
Herba Artemisiae Anomalae 14g;
Herba Erodii 36g;
Hirudo 4g;
Female ground beetle 4g.
Embodiment five: a kind of pharmaceutical composition of anti-hepatic fibrosis
The pharmaceutical composition prescription is made up of the following raw materials in weight medicine:
Herba Artemisiae Anomalae 13g;
Herba Erodii 12g;
Hirudo 2g;
Female ground beetle 2g.
Clinical practice example: adopt prescription of the present invention to make oral liquid formulations, above and compensatory phase patient 60 examples of liver cirrhosis for the treatment of chronic hepatitis moderate, and to take 60 examples that Herba Sidae Rhombifoliae soup adds the essentiale capsule for treating in contrast, obtain satisfactory effect, now be reported as follows:
1. clinical data: select the above and compensatory phase patient of liver cirrhosis of chronic hepatitis moderate totally 120 examples, be the outpatient of the court, be divided into treatment group and matched group at random.60 examples are organized in treatment, moderate chronic hepatitis 40 examples wherein, severe 10 examples, compensatory phase patient 10 examples of liver cirrhosis; Male 50 examples wherein, women 10 examples, age 19-63 year, course of disease 2-15; Matched group 60 examples, situation is near with the treatment winding, and two groups of clinical data no significant differences have comparability preferably.The selected equal display abnormality of case Serum hyaluronic acid (HA) familial combined hyperlipidemia collagen.
2. the diagnostic criteria of hepatic fibrosis:
2.1 the liver biopsy pathology checks: being still the goldstandard of diagnosing liver fibrosis, is the important evidence of clarifying a diagnosis, weighing inflammation mobility, fibrosis and judge curative effect of medication.Generally adopt the sxemiquantitative scoring system at present.But, because hepatic fibrosis skewness in liver, and liver puncture organize only account for 50,000 of full liver/, can cause Error Diagnostics.Therefore emphasize liver biopsy specimen at least 15 mm, and comprise 6 above portal areas.
2.2 imaging examination: B ultrasonic has good dependency to liver surface, liver echo, hepatic vein, liver edge and 5 parameters of spleen area and hepatic fibrosis by stages, but to the difficult differentiation of 1 ~ 3 phase.Also the someone thinks that the degree of the maximum isoparametric change of clino-diagonal of main portal vein, portal vein per minute blood flow parameter, spleen thickness, splenic vein width and right lobe of liver and hepatic fibrosis has dependency preferably.
2.3 biochemical detection: Serum hyaluronic acid (HA), laminin (LN), III procollagen type (PCIII), type (CIV) can reflect degree of hepatic fibrosis, particularly HA and PCIII are the highest to the value of early stage hepatic fibrosis, also are subjected to the influence of liver inflammation degree simultaneously.
2.4 color doppler ultrasonography helps to estimate the degree of hepatic fibrosis, because during hepatic fibrosis, hepatic artery blood flow speed increases, portal venous flow speed slows down, therefore the ratio of the two can reflect more fully that the hemodynamics of hepatic fibrosis changes, and is better than measuring merely the detection of portal vein flow velocity or the change of hepatic vein frequency spectrum.
3. Therapeutic Method: the treatment group is taken " easing the affected liver oral liquid " (every 10ml contains Herba Artemisiae Anomalae crude drug 10g, Herba Erodii crude drug 15g, Hirudo crude drug 3g, female ground beetle crude drug 3g), each oral 10ml, and every day three times, serveing on 3 months is a course for the treatment of; Matched group is taken Herba Sidae Rhombifoliae soup and is added the essentiale capsule.Herba Sidae Rhombifoliae soup is formed: Radix Bupleuri 10g, Radix Scutellariae 10g, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens) 10g, Radix Codonopsis 10g, Rhizoma Zingiberis Recens 3g, Radix Glycyrrhizae 5g, every day, potion was fried in shallow oil the secondary clothes.Essentiale every day three times, each two.Two groups is a course for the treatment of to treat 3 months all, adds up therapeutic effect after 2 courses for the treatment of.
4. observation index and method: observe Serum hyaluronic acid (HA), type (C IV), the laminin (LN) of hepatic fibrosis serum in checking, all adopt radioimmunology, test kit is provided by Shanghai INM biotechnology center.Alanine aminotransferase (ALT) and gamma Globulin (γ-G) detect according to general routine biochemistry inspection.MethodsThe cases enrolled is done comprehensive health check-up before dispensing, and gets blood 10ml, and except looking into liver function and hepatitis b virus marker, it is frozen in-80 ℃ of cryogenic refrigerators to isolate 3ml serum, and treatment finishes the back by the unified hepatic fibrosis index that detects.
5. therapeutic outcome
5.1 hepatic fibrosis index: every measured value of normal person and healthy blood donation personnel is respectively HA 57 ± 27ng/ml, C IV 49.77 ± 15.0ug/L, and LN 115.7 ± 17.3ng/ml, two groups of hepatic fibrosis index levels relatively see table 1 for details before and after the treatment.
HA, C IV, LN level change (X ± S, i.e. mean+SD) before and after the table 1 liang group treatment
As can be seen from Table 1, before treating after treatment, the HA level of matched group obviously descends (P＜0.05), before treating after treatment, the C IV level of matched group obviously descends (P＜0.05), before treating after treatment, the HA level for the treatment of group obviously descends (P＜0.01), before treating after treatment, the C IV level for the treatment of group obviously descends (P＜0.01), before treating after treatment, the LN level for the treatment of group obviously descends (P＜0.05), the HA level for the treatment of group is obviously descending (P＜0.05) after than treatment of control group after the treatment, and the C IV level for the treatment of group is in obviously descend after than treatment of control group after the treatment (P＜0.05).In a word, the easing the affected liver oral liquid can significantly reduce HA in the serum, LN, C IV level, also can significantly reduce HA, C IV level and Herba Sidae Rhombifoliae soup adds essentiale.
5.2 (influence of γ-G) the results are shown in Table 2 to alanine aminotransferase (ALT) and gamma Globulin.
The variation of ALT and γ-G before and after the table 2 liang group treatment (X ± S)
| ? | Case load | ALT | ALT | Case load | γ-G | γ-G |
| ? | n | Before the treatment | After the treatment | n | Before the treatment | After the treatment |
| The treatment group | 60 | 193.45±35.07 | 78.63±20.46 | 60 | 31.93±15.17 | 20.27±8.32 |
| Matched group | 60 | 190.05±25.86 | 94.39±23.14 | 60 | 32.23±10.75 | 24.42±7.61 |
As can be seen from Table 2, the ALT content for the treatment of group obviously reduces (P＜0.01) before the treatment after treatment, the γ for the treatment of group-G content obviously reduces (P＜0.05) before the treatment after treatment, i.e. treatment group ALT and γ-G content after easing the affected liver mixture treatment obviously reduce, and have highly significant (P＜0.01) and significance (P＜0.05), but with matched group relatively, no significant difference then, illustrate two groups all effective.
5.3 disease situation of change before and after the treatment.Tired weak, the vexed poor appetite of gastral cavity of two groups of patient's bodies, side of body rib dull pain, dizzy order are puckery, abdominal distention loose stool, the side of body down sings and symptomses such as mass in the abdomen (hepatosplenomegaly), body of the tongue stasis of blood purple, liver palm, spider angioma in various degree improvement is all arranged, no significant difference between two groups (P〉0.05) after treatment.
Above-described embodiment only is explanation technical conceive of the present invention and characteristics, and its purpose is to allow the personage who is familiar with this technology can understand content of the present invention and enforcement according to this, can not limit protection scope of the present invention with this.All equivalences that spirit is done according to the present invention change or modify, and all should be encompassed within protection scope of the present invention.
Claims (2)
1. the pharmaceutical composition of an anti-hepatic fibrosis, it is characterized in that: the crude drug by following parts by weight is formed:
Herba Artemisiae Anomalae 5-15 part;
Herba Erodii 10-20 part;
Hirudo 1-5 part;
Female ground beetle 1-5 part.
2. the pharmaceutical composition of anti-hepatic fibrosis according to claim 1, it is characterized in that: the crude drug by following parts by weight is formed:
Herba Artemisiae Anomalae 7-13 part;
Herba Erodii 12-18 part;
Hirudo 2-5 part;
Female ground beetle 2-5 part.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310194381.7A CN103251669B (en) | 2013-05-23 | 2013-05-23 | Anti-hepatic fibrosis drug composite |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310194381.7A CN103251669B (en) | 2013-05-23 | 2013-05-23 | Anti-hepatic fibrosis drug composite |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103251669A true CN103251669A (en) | 2013-08-21 |
| CN103251669B CN103251669B (en) | 2014-07-23 |
Family
ID=48956102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310194381.7A Active CN103251669B (en) | 2013-05-23 | 2013-05-23 | Anti-hepatic fibrosis drug composite |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103251669B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102058765A (en) * | 2010-11-19 | 2011-05-18 | 天津太平洋制药有限公司 | Chinese medicine preparation for treating cirrhosis and preparation method thereof |
| CN102218104A (en) * | 2010-04-15 | 2011-10-19 | 张立中 | Traditional Chinese medicine preparation for preventing liver fibrosis and treating liver cirrhosis |
-
2013
- 2013-05-23 CN CN201310194381.7A patent/CN103251669B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102218104A (en) * | 2010-04-15 | 2011-10-19 | 张立中 | Traditional Chinese medicine preparation for preventing liver fibrosis and treating liver cirrhosis |
| CN102058765A (en) * | 2010-11-19 | 2011-05-18 | 天津太平洋制药有限公司 | Chinese medicine preparation for treating cirrhosis and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 刘翔: "江一平治疗慢性肝炎肝纤维化经验", 《江西中医药》 * |
| 岳煜等: "肝纤维化中医药研究进展", 《中医学报》 * |
| 李川等: "单味中药抗肝纤维化机制研究概述", 《环球中医药》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103251669B (en) | 2014-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104491733A (en) | Application of traditional Chinese medicine preparation in preparation of medicines for treating anemia, deficiency of vital energy and debilitation | |
| CN103083592A (en) | Traditional Chinese medicine for treating gouty arthritis | |
| CN103041241B (en) | Compound psoriasis arthropathica removal decoction | |
| CN104840783A (en) | Traditional Chinese medicine preparation for treating urinary calculus and preparation method of traditional Chinese medicine preparation | |
| CN105833184B (en) | A kind of Chinese medicine composition, fermentation medical fluid of its preparation and preparation method and application | |
| CN103251669B (en) | Anti-hepatic fibrosis drug composite | |
| CN103705846A (en) | Traditional Chinese medicine preparation for treating ovarian cyst | |
| CN104042681B (en) | Be used for the treatment of the external decoction of urticaria | |
| CN105902897A (en) | Pharmaceutical preparation for treating pancreatic cancer and application thereof | |
| CN104825925A (en) | Traditional Chinese medicine for treating leukorrhagia | |
| CN104258222A (en) | Traditional Chinese medicine composition for treating polycythemia vera | |
| CN116999486B (en) | Zhuang medicine compound medicine for treating ischemic stroke convalescence and preparation method thereof | |
| CN108524828A (en) | Treat the Chinese medicine composition and its preparation method and application of cirrhotic ascites | |
| CN103721019B (en) | A kind of Chinese medicine composition improving rheumatoid arthritis | |
| CN102327435A (en) | Traditional Chinese herb preparation for treating gout | |
| Jinghui et al. | The prescription rule analysis of the new theory on spleen dampness syndrome by academician TONG Xiaolin | |
| CN106727752A (en) | Treat pharmaceutical composition of synovitis and preparation method thereof | |
| CN101829312A (en) | Medicament for treating rheumatoid arthritis and preparation method thereof | |
| CN106728582A (en) | Treat the Chinese medicine of recovery period of stroke | |
| CN106421694A (en) | Externally used Chinese herba preparation for treating dysmenorrhea | |
| CN105213975A (en) | A kind of pharmaceutical composition and application thereof for the treatment of liver cirrhosis | |
| CN105327295A (en) | Capsules for treating hepatitis and preparing method thereof | |
| CN105106922A (en) | Decoction medicine for treating stomach cancer postoperative fever and preparation method of decoction medicine | |
| CN104666824A (en) | Traditional Chinese medicinal composition for treating psoriasis | |
| CN104784649A (en) | Traditional Chinese medicine decoction for treating scapulohumeral periarthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |